BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21205142)

  • 1. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
    Sonneveld MJ; Janssen HL
    Liver Int; 2011 Jan; 31 Suppl 1():78-84. PubMed ID: 21205142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M; Invernizzi F; Lampertico P
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
    Rijckborst V; Sonneveld MJ; Janssen HL
    Aliment Pharmacol Ther; 2011 Mar; 33(5):501-13. PubMed ID: 21198707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
    Papatheodoridis GV
    Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2015 Jan; 35 Suppl 1():100-6. PubMed ID: 25529094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
    Buti M
    Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
    Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
    J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferon in hepatitis B].
    García Buey L; González Mateos F; Moreno Otero R
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
    Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
    Tornai I
    Orv Hetil; 2011 May; 152(22):869-74. PubMed ID: 21565754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in the treatment of chronic hepatitis B.
    Hadziyannis SJ
    Expert Opin Biol Ther; 2006 Sep; 6(9):913-21. PubMed ID: 16918258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of patients affected by HBeAg-negative chronic hepatitis B.
    Marcellin P; Boyer N; Asselah T
    Minerva Gastroenterol Dietol; 2006 Mar; 52(1):23-38. PubMed ID: 16554704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
    Leung N
    Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.
    Matsumoto A; Nishiguchi S; Enomoto H; Kang JH; Tanaka Y; Shinkai N; Kurosaki M; Enomoto M; Kanda T; Yokosuka O; Yatsuhashi H; Nagaoka S; Okuse C; Kagawa T; Mine T; Takaguchi K; Saito S; Hino K; Ikeda F; Sakisaka S; Morihara D; Miyase S; Tsuge M; Chayama K; Hiramatsu N; Suzuki Y; Murata K; Tanaka E
    J Gastroenterol; 2018 Feb; 53(2):247-257. PubMed ID: 28634723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
    Buster EH; Janssen HL
    Neth J Med; 2006 Jun; 64(6):175-85. PubMed ID: 16788215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.